A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

NCT02392624 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Urticaria

Interventions

DRUG: Omalizumab
DRUG: Placebo

Sponsor

Genentech, Inc.